Targeting Molecular and Cellular Mechanisms in SARS-CoV-2 Novel Coronavirus Disease 2019 (COVID-19)

Majhi, S; Dua, K; Prasher, P; Narayan Yadav, H; Singh, L

Targeting Molecular and Cellular Mechanisms in SARS-CoV-2 Novel Coronavirus Disease 2019 (COVID-19)

Majhi, S Dua, K

Prasher, P Narayan Yadav, H Singh, L

Permalink

Publisher:: Springer
Publication Type:: Chapter
Citation:: Targeting Cellular Signalling Pathways in Lung Diseases, 2021, pp. 517-536
Issue Date:: 2021-07-03

Closed Access

	Filename	Description	Size
	978-981-33-6827-9_24.pdf	Published version	501.7 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Majhi, S
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Prasher, P
dc.contributor.author	Narayan Yadav, H
dc.contributor.author	Singh, L
dc.date.accessioned	2023-01-10T22:03:14Z
dc.date.available	2023-01-10T22:03:14Z
dc.date.issued	2021-07-03
dc.identifier.citation	Targeting Cellular Signalling Pathways in Lung Diseases, 2021, pp. 517-536
dc.identifier.isbn	978-981-33-6826-2
dc.identifier.uri	http://hdl.handle.net/10453/164814
dc.description.abstract	Coronavirus disease 2019 (COVID-19) represents a significant threat to global well-being and safety. Controlling it and reducing the rate of death as soon as possible is a pressing job for the healthcare sector. The possible therapeutic agents used in COVID-19 are from the past encounters in combating SARS, MERS, and other viruses. Assuming that broad-spectrum antiviral drugs have long been accepted on the market to treat various infectious diseases, their metabolic features, dosage, possible efficacy, and side effects are yet to be studied for the current scenario. Repurposing of clinically approved drugs may be a salient short-term approach for the treatment of novel coronavirus. But the downside is that these therapies are too “broad spectrum” to target COVID-19 directly. Therefore, its side effects cannot be underrated. A number of clinical trials are underway to evaluate the effectiveness of other treatment options. Active symptomatic support is still the key to treatment. Although stem cells, monoclonal antibodies, polypeptides, interferon, and plasma from recovered patients have been shown to be effective in treating COVID-19 patients, their safeties are still being evaluated, and the efficacy remains to be further confirmed. This chapter illuminates the structural proteins of SARS-CoV-2 and helps to investigate certain proteins and gain new insights into the drugs used for COVID-19. The features of future therapy must be multicomponent, multitarget, and multi-pathway for disease, care and it has tremendous potential for COVID-19 therapy. Because the pandemic is rapidly emerging, such observations will lead to better understanding for making effective therapeutics to curb COVID-19.
dc.format.extent	39
dc.language	en
dc.publisher	Springer
dc.relation.ispartof	Targeting Cellular Signalling Pathways in Lung Diseases
dc.relation.isbasedon	10.1007/978-981-33-6827-9_24
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Targeting Molecular and Cellular Mechanisms in SARS-CoV-2 Novel Coronavirus Disease 2019 (COVID-19)
dc.type	Chapter
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2023-01-10T22:03:08Z
pubs.place-of-publication	Switzerland
pubs.publication-status	Published
dc.location	Switzerland

Abstract:

Coronavirus disease 2019 (COVID-19) represents a significant threat to global well-being and safety. Controlling it and reducing the rate of death as soon as possible is a pressing job for the healthcare sector. The possible therapeutic agents used in COVID-19 are from the past encounters in combating SARS, MERS, and other viruses. Assuming that broad-spectrum antiviral drugs have long been accepted on the market to treat various infectious diseases, their metabolic features, dosage, possible efficacy, and side effects are yet to be studied for the current scenario. Repurposing of clinically approved drugs may be a salient short-term approach for the treatment of novel coronavirus. But the downside is that these therapies are too “broad spectrum” to target COVID-19 directly. Therefore, its side effects cannot be underrated. A number of clinical trials are underway to evaluate the effectiveness of other treatment options. Active symptomatic support is still the key to treatment. Although stem cells, monoclonal antibodies, polypeptides, interferon, and plasma from recovered patients have been shown to be effective in treating COVID-19 patients, their safeties are still being evaluated, and the efficacy remains to be further confirmed. This chapter illuminates the structural proteins of SARS-CoV-2 and helps to investigate certain proteins and gain new insights into the drugs used for COVID-19. The features of future therapy must be multicomponent, multitarget, and multi-pathway for disease, care and it has tremendous potential for COVID-19 therapy. Because the pandemic is rapidly emerging, such observations will lead to better understanding for making effective therapeutics to curb COVID-19.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/164814